Page 7 - Pediatric Disease News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Abeona Therapeutics Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

CLEVELAND, July 03, 2023 Abeona Therapeutics Inc. today announced that it has raised $25 million at-the-market from select existing investors, primarily to fund initiation of the.

New yorkUnited statesAbeona therapeutics incCantor fitzgerald coSecurities exchangeCorporate communicationsExchange commissionGlobenewswire incNantahala capital managementAlliance global partnersLicense applicationCapital managementGlobal partnersPediatric diseaseCapital marketsSecurities act

Abeona Therapeutics (ABEO) Announces $25 Million Registered Direct Offering of Common Stock, Warrants

Abeona Therapeutics (ABEO) Announces $25 Million Registered Direct Offering of Common Stock, Warrants
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesAbeona therapeutics incGp alliance global partnersExchange commissionNantahala capital managementCantor fitzgerald coAbeona therapeuticsLicense applicationAdage capital partnersAlliance global partnersPediatric diseaseCantor fitzgeraldEquity capital markets

Eiger BioPharmaceuticals to Focus on Metabolic Diseases with Avexitide; David Apelian Takes Helm as CEO

Prioritizing resources to advance avexitide in hyperinsulinemic hypoglycemia indicationsActive discussions underway with potential partners to advance late-stage virology programsReduction in workforce executed to align with focus on avexitide; ext.

Aljanae reynoldsProgeroid laminopathiesSylvia wheelerBristol myers squibbThomas dietzBluesphere bioDavid apelianAchillion pharmaceuticals incPrnewswire eiger biopharmaceuticals incSchering ploughRegulatory affairsEiger biopharmaceuticals incChief executive officerChief operating officerPost bariatric hypoglycemiaBreakthrough therapy

DepYmed Presents Development Update for its Small Molecule PTP1B Inhibitor Program, DPM-1003, at the 2023 IRSF Rett Syndrome Scientific Meeting

DepYmed Presents Development Update for its Small Molecule PTP1B Inhibitor Program, DPM-1003, at the 2023 IRSF Rett Syndrome Scientific Meeting
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesCold spring harbor laboratoryNicholas tonksJules abrahamPartners incDepymed incNashville marriott at vanderbilt university inDrug administrationInternational rett syndrome foundationInternational rett syndrome associationRett syndrome research foundationRett syndromeRett syndrome foundationRett syndrome scientificNashville marriott

DepYmed to Present Early Data on Its Small Molecule PTP1B Inhibitor Program at the 2023 IRSF Rett Syndrome Scientific Meeting

DepYmed to Present Early Data on Its Small Molecule PTP1B Inhibitor Program at the 2023 IRSF Rett Syndrome Scientific Meeting
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesCold spring harbor laboratoryNashville marriott at vanderbilt university inDepymed incDrug administrationRett syndrome research foundationJules abrahamjqa partners incInternational rett syndrome associationInternational rett syndrome foundationWall streetRett syndrome foundationRett syndrome scientificNashville marriottVanderbilt universityRett syndrome